Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the pricing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE